Karen Wagner, PhD
Venture Partner
kwagner@ysioscapital.com

Karen supports the team of Ysios Capital Partners, particularly for the identification and evaluation of investment opportunities.

Karen works with several biotechnology companies as an independent consultant in business development and licensing besides her professional relationship with Ysios.

Prior to becoming an independent consultant and Venture Partner with Ysios, Karen was a Global Alliance Director for F. Hoffmann-La Roche in Basel , with responsibility to secure for Roche's Global Research Function a number of key technologies for drug discovery as well as compounds for treatment of oncological and viral diseases. Among other transactions, Karen was project leader for the the Alnylam-Roche collaboration announced in July 2007, valued at over USD 1 billion and one of Allicense' Key Deals of the year. She joined Roche from GLYCART where she worked together with Joel Jean-Mairet. At GLYCART, Karen was responsible for business development, negotiating key in- and out-licensing agreements and contributing to the sale of the company to Roche in 2005. From 2001 to 2004, Karen was a Business Development Director for Ingenium Pharmaceuticals in Munich . Before that, Karen was a consultant and member of McKinsey & Company's Global Healthcare Practice.

Karen holds a master's degree in Molecular Biology and a doctorate in the field of Cell Biology from the University of Konstanz, Germany.

top